NASDAQ
9.54USD
+0.21 (+2.25%)
We have scored 10 news catalysts on Keros Therapeutics, Inc. (KROS) over the past 12 months. The biggest single-day move next to one of them came Mar 5, 2026, when KROS closed −15.0%: “Can Reblozyl Stabilize BMY's Top Line Amid Legacy Drugs Decline?”. Coverage across the window leans positive (average ticker sentiment +0.28). Most of the impact sits in sector healthcare and downstream customer concentration.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
187.2M
P/E
—
EPS
—
Beta
1.02
52W range
8.98-22.55
Day range
9.23–9.72
Open
9.37
Prev close
9.33
Volume
221.7K
Avg volume
190.3K
Dividend
0.00
IPO
2020-04-08
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Keros Therapeutics, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for KROS: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.
